Title |
Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model
|
---|---|
Published in |
Malaria Journal, January 2015
|
DOI | 10.1186/1475-2875-14-8 |
Pubmed ID | |
Authors |
Efrem T Abay, Jan H van der Westuizen, Kenneth J Swart, Liezl Gibhard, Nina Lawrence, Ntokozo Dambuza, Anke Wilhelm, Kendrekar Pravin, Lubbe Wiesner |
Abstract |
Even though malaria is a completely preventable and treatable disease, it remains a threat to human life and a burden to the global economy due to the emergence of multiple-drug resistant malaria parasites. According to the World Malaria Report 2013, in 2012 there were an estimated 207 million malaria cases and 627,000 deaths. Thus, the discovery and development of new, effective anti-malarial drugs are required. To achieve this goal, the Department of Chemistry at the University of the Free State has synthesized a number of novel amino-alkylated chalcones and analogues, which showed in vitro anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum strains. The lead compound (NP046) was selected for a comprehensive pharmacokinetic (PK) and in vivo efficacy evaluation in a mouse model. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 3% |
Unknown | 35 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 25% |
Researcher | 4 | 11% |
Student > Bachelor | 4 | 11% |
Other | 3 | 8% |
Student > Postgraduate | 3 | 8% |
Other | 8 | 22% |
Unknown | 5 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 33% |
Agricultural and Biological Sciences | 8 | 22% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
Chemistry | 3 | 8% |
Computer Science | 1 | 3% |
Other | 3 | 8% |
Unknown | 5 | 14% |